UBS Reiterates Buy Rating on Surgery Partners (SGRY) Following Activist Letter to Shareholders

March 11, 2026 9:46 AM

UBS analyst AJ Rice reiterated a Buy rating and $21.00 price target on Surgery Partners (NASDAQ: SGRY).The analyst commented, "At ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found